UK markets closed

Amicus Therapeutics, Inc. (0HF9.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
9.97+0.34 (+3.53%)
At close: 06:23PM BST
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.79
52-week change 34.42%
S&P500 52-week change 328.04%
52-week high 314.57
52-week low 39.74
50-day moving average 313.10
200-day moving average 312.19

Share statistics

Avg vol (3-month) 3814
Avg vol (10-day) 3248
Shares outstanding 5189.29M
Implied shares outstanding 6N/A
Float 8238.52M
% held by insiders 10.72%
% held by institutions 1109.60%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin -34.73%
Operating margin (ttm)-19.63%

Management effectiveness

Return on assets (ttm)-5.08%
Return on equity (ttm)-126.10%

Income statement

Revenue (ttm)423.49M
Revenue per share (ttm)1.42
Quarterly revenue growth (yoy)28.00%
Gross profit (ttm)N/A
EBITDA -49.02M
Net income avi to common (ttm)-147.07M
Diluted EPS (ttm)-0.97
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)239.6M
Total cash per share (mrq)0.81
Total debt (mrq)444.49M
Total debt/equity (mrq)340.10%
Current ratio (mrq)3.04
Book value per share (mrq)0.44

Cash flow statement

Operating cash flow (ttm)-80.72M
Levered free cash flow (ttm)-37.5M